| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
EC50: 16-120 μM (Rho family GTPases)[1]
Rho family GTPases. MLS000532223 is a high-affinity, selective inhibitor of the Rho family of GTPases. It prevents GTP binding to these proteins, thereby inhibiting their activity. This blockade affects downstream signaling pathways that regulate the actin cytoskeleton, cell migration, and other critical cellular functions. It has EC50 values ranging from 16 μM to 120 μM. |
|---|---|
| ln Vitro |
GTP binding to several GTPases is inhibited by MLS000532223 in a dose-dependent manner[1]. The kinetics of Rho-family GTP binding are modulated by MLS000532223[1]. Actin rearrangements and alterations in cell morphology that follow Rho family GTPase activation are inhibited by MLS000532223[1]. In mast cells, MLS000532223 (10 μM) modifies actin remodeling[1]. RBL units [1].
MLS000532223 is a high-affinity inhibitor of Rho family GTPases, with EC50 values ranging from 16 μM to 120 μM. It prevents GTP binding to several GTPases in a dose-dependent manner and is active in biochemical and cell-based secondary assays. Live-cell imaging and confocal microscopy studies have revealed that the inhibitor causes actin reorganization and changes in cell morphology, which are characteristic of Rho GTPase inhibition. |
| ln Vivo |
In vivo, MLS000532223 would be used to study the role of Rho GTPases in various physiological and pathological processes. By inhibiting these key signaling proteins, the compound can modulate cell migration, adhesion, and proliferation. Its effects on actin reorganization and cell morphology are critical for understanding the function of Rho GTPases in development, immunity, and cancer.
|
| Enzyme Assay |
The in vitro activity of MLS000532223 is assessed using biochemical assays that measure its ability to prevent GTP binding to Rho GTPases. Typically, purified Rho proteins are incubated with a fluorescent or radiolabeled GTP analog in the presence of the compound, and the amount of bound nucleotide is measured. This allows for the determination of its inhibitory potency (EC50).
|
| Cell Assay |
Cellular assays for MLS000532223 involve treating cells with the compound and assessing its effects on Rho GTPase-dependent processes. For example, changes in the actin cytoskeleton, such as the loss of stress fibers or the formation of actin aggregates, can be visualized using fluorescently labeled phalloidin. These morphological changes confirm that the compound is inhibiting Rho GTPases within the cell.
|
| Animal Protocol |
In vivo studies with MLS000532223 would be performed in animal models to investigate the role of Rho GTPases in disease. For example, in cancer research, the compound could be administered to tumor-bearing mice to assess its effects on tumor growth, metastasis, and angiogenesis. Its ability to inhibit Rho GTPase-mediated cell migration and invasion would be a key area of interest.
|
| ADME/Pharmacokinetics |
MLS000532223 is a small molecule with the molecular formula C15H9NO3 and a molecular weight of 251.24. Its pharmacokinetic properties, such as bioavailability and half-life, would be key factors for its utility in in vivo studies. As a research compound, its cellular activity and specificity are well characterized.
|
| Toxicity/Toxicokinetics |
No specific toxicity data is available for MLS000532223. As an inhibitor of Rho GTPases, which are critical regulators of many cellular processes, its toxicity profile would be an important consideration. Potential toxicities could be related to its effects on normal cell function. Standard preclinical safety studies would be needed to evaluate its safety.
|
| References | |
| Additional Infomation |
1-(3-nitrophenyl)-3-phenyl-2-propyn-1-one is an aromatic compound.
MLS000532223 (CAS#: 16616-39-0) is a potent and selective inhibitor of Rho family GTPases. It has EC50 values ranging from 16 μM to 120 μM. It prevents GTP binding to these proteins and is active in biochemical and cell-based assays. It is a research tool for studying Rho GTPase function and is not approved for clinical use. |
| Molecular Formula |
C15H9NO3
|
|---|---|
| Molecular Weight |
251.24
|
| Exact Mass |
251.058
|
| CAS # |
16616-39-0
|
| PubChem CID |
781112
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
3.352
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
19
|
| Complexity |
406
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C(C=C1)C#CC(=O)C2=CC(=CC=C2)[N+](=O)[O-]
|
| InChi Key |
JODIUOIVYGKAJH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H9NO3/c17-15(10-9-12-5-2-1-3-6-12)13-7-4-8-14(11-13)16(18)19/h1-8,11H
|
| Chemical Name |
1-(3-nitrophenyl)-3-phenylprop-2-yn-1-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 50 mg/mL (199.01 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.9803 mL | 19.9013 mL | 39.8026 mL | |
| 5 mM | 0.7961 mL | 3.9803 mL | 7.9605 mL | |
| 10 mM | 0.3980 mL | 1.9901 mL | 3.9803 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
